Clinical Trial Update: Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B [Phase 1]

View source ↗

Summary

Phase I study evaluating safety and immunogenicity of FP-02.2 in chronic hepatitis B completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• FP-02.2

Snippet

Sponsor: Altimmune, Inc. | Conditions: Hepatitis B | Phase 1 | Status: COMPLETED | Results posted: 2025-05-22